The ExoDx™ Prostate Test
Introducing the only exosome-based prostate cancer test delivering unique, actionable intelligence to help you decide if prostate biopsy is necessary, independent of PSA and other standard of care (SOC) information.
Now available as an At-Home Collection Kit!
Assess prostate cancer risk
Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer
Precisely predictive, clinically convenient
Simple urine test, non-DRE, included in the NCCN guidelines to help guide your patient to biopsy decision
A new standard in prostate risk assessment
Clinical studies demonstrate the ExoDx Prostate test discriminates between high-grade and low-grade prostate cancer and benign disease
A treasure trove of RNA, DNA and protein
Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs
What's New
-
Image
Entering the Chat Room of Cancer Cells - How They Talk and Why We Should Listen
-
Image
How the ExoDx Prostate Test Impacts Urology Practice in a Real-World Clinical Setting
-
Image
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study
-
-
Image
ExoDx Prostate Test: Implications for Value-Based Care
-
Image
Beyond PSA: The ExoDx Prostate™ test (EPI) as a Precision Genomic Biomarker
-
Image
Learn About Research and Clinical Applications of Exosome Based Liquid Biopsies
-
Image
Medicare Issues Final Local Coverage Decision for Bio-Techne's ExoDx Prostate (Intelliscore) Test
-
Image
FDA Grants Breakthrough Device Designation to Bio-Techne's ExoDx Prostate (IntelliScore) (EPI) Test
-
Image
ExoDx Prostate(IntelliScore) (EPI) Included in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Stay in Touch with ExosomeDx
Join our Mailing LIstReceive updates and scientific advances
Meet the ExosomeDx Team
The ExoDx Prostate test is a simple urine test that detects three important genomic biomarkers that are markers of high-grade prostate cancer. Using this assessment, the physician can determine whether or not a patient should undergo a diagnostic biopsy.
Gaining access to molecular information from biofluids without needing direct access to the tissue itself will have far-reaching implications in patient management. While our diagnostics are initially focused on cancer, our exosome-based technology platform is potentially applicable to other diseases or medical conditions where molecular testing is beneficial, but where access to tissue is difficult or impossible.
"To us, it's all about the patients and helping them through the process. This changes everything" - Dr. Johan Skog, Chief Scientific Officer:
Partner with Exosome Diagnostics
Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".
Johan is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael is the Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.